IMAAVY — Class II drug recall D-0016-2027
Ongoing recall by J&J INNOVATIVE MEDICINE, reported 2026-10-14, distributed in OH. Presence of particulate matter.
| Recall number | D-0016-2027 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | J&J INNOVATIVE MEDICINE, Malvern, PA, United States |
| Recall initiated | 2026-09-23 |
| Classified | 2026-10-08 |
| Reported by FDA | 2026-10-14 |
| Distributed | OH |
| Quantity | 49 vials |
| Reason classes | specification failure |
| NDC | 57894-0800, 57894-0800-01, 57894-0801, 57894-0801-01 |
| Lot numbers | JNYJ1208 |
| Expiration dates | 2027-10-30 |
Product
IMAAVY (nipocalimab-aahu) Injection, 300 mg /1.62 mL (185 mg/mL) per single-dose vial, For Intravenous Infusion After Dilution, Rx only, Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044. NDC: 57894-800-01
Reason for recall
Presence of particulate matter.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0016-2027. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-10-21. Not affiliated with or endorsed by FDA. Not medical or legal advice.